medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2009, Number 10

<< Back Next >>

Ginecol Obstet Mex 2009; 77 (10)

Intrauterine misoprostol for the prevention of bleeding cesarean

Quiroga DR, Cantú MR, Tello GHE, Puente VM, Montemayor GR, Martínez MA

Language: Spanish
References: 13
Page: 469-474
PDF size: 223.99 Kb.


ABSTRACT

Objective: To evaluate efficacy of misoprostol by intrauterine route for the prevention of the obstetrical hemorrhage and to know its effects collaterals.
Patients and methods: Clinical and randomized test with 200 patients to those who one took place to them Caesarean. The Group A was applied placebo and the group B misoprostol (group B; 800 µg) intrauterine, after the birth of its newborns. The necessity of additional uterotonics was compared, loss of hemoglobin and hematocrit, and the effects collaterals.
Results: In group B it diminished the necessity of additional uterotonics to 50% and the loss of hemoglobin in 39.6%. In the group greater loss of 3 was registered g of hemoglobin in 13 versus 3% of the patients. With respect to the hematocrit, its loss was reduced in 40.6%. The patients in those who the hematocrit in more fell than 10%, registered themselves in 7 versus 1% cases. The effects collaterals were few and not so serious.
Conclusion: The intrauterine combination of misoprostol and oxitocin diminishes the postcaesarean sanguineous loss and has brings about few effects collaterals.


REFERENCES

  1. Printchard JA, Baldwin RM, Dicker JC, Wiggins KM. Blood volumen changes in pregnancy and the puerperium. Am J Obstet Gynecol 1962;84:1271-82.

  2. Clark SL, Yeh SY, Phelan JP, Bruce S, Paul RH. Emergency hysterectomy for obstetric hemorrhage. Obstet Gynecol 1984;64:376-80.

  3. Fernández CS. Índices de mortalidad materna. Dirección General de Estadística e Informática. Secretaría de Salud. México, 1990-1996.

  4. Turmen T. Safe motherhood: a global problem. Report from a symposium on the prevention and management of anaemia in pregnancy and postpartum hemorrhage. World Health Organization. Zurich, 1996:1-13.

  5. Drife J. Management of primary postpartum haemorrhage (commentary). Br J Obstet Gynaecol 1997;104:275-7.

  6. Hogerzeil HV, Walker GJA, de Goeje MJ. Stability of injectable oxytocics in tropical climates. Geneva: World Health Organization, 1993.

  7. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 76, October 2006: postpartum hemorrhage. Obstet Gynecol 2006;108:1039-47

  8. Pendiville WL, Harding JE, Elbourne DR, Stirrat GM. The Bristol third stage trial:actives versus physiological management of third stage of labour. BMJ 1988;197:1295-300.

  9. el-Refaey H, Hinshaw K, Templeton A. The abortifacient effect of misoprostol in the second trimester. Hum Reprod1993;8:1744-6.

  10. Sánchez-Ramos L, Kaunitz AM. Misoprostol for cervical ripening and labor induction; a systematic review of the literature. Clin Obstet Gynecol 2000;43:475-88.

  11. el-Refaey H, O'Brien P, Morafa W, Walder J, Rodeck C. Use of oral misoprostol in the prevention of postpartum haemorrhage. Br J Obstet Gynaecol 1997;104;336-9.

  12. Bamigboye AA, Hofmeyr GJ, Merrell DA. Coronation HospitalJohannesburg, South Africa. Rectal misoprostol in the prevention of postpartum hemorrhage. Am J Obstet Gynaecol 1998:179;1043-6.

  13. Quiroga DR, Esparza AM. Misoprostol vaginal para la prevención de la hemorragia posparto. Ginecol Obstet Mex 2002;70:572-5.




2020     |     www.medigraphic.com